Literature DB >> 11132741

Continuous nicardipine infusion to control blood pressure after evacuation of acute cerebral hemorrhage.

T Nishiyama1, T Yokoyama, T Matsukawa, K Hanaoka.   

Abstract

PURPOSE: To explore the long-term effects of the calcium antagonist, nicardipine, on cerebral hemodynamics in patients with acute cerebral hemorrhage, we investigated the effects of nicardipine infusion on intracranial pressure (ICP), middle cerebral arterial blood flow velocity (Vmca) , and computed tomographical (CT) findings of bleeding and edema.
METHODS: Twenty-two patients with acute cerebral hemorrhage were infused with nicardipine for > 72 hr to decrease blood pressure. Blood pressure, heart rate, conscious level, Vmca, pulsatility index (PI, using transcranial Doppler), ICP, cerebral perfusion pressure (CPP) and platelet counts were monitored. CT examination was also performed to detect the changes of bleeding (hematoma) and/or brain edema.
RESULTS: Blood pressure decreased (20 to 30% from control, P < 0.05) without any changes in heart rate. Platelet count did not change neither did Vmca and PI change on either the intact or injured side. The ICP decreased 24 hr after the end of infusion from 30 +/- 12 mmHg to 20 +/- 9 mmHg (P = 0.036) but was still higher than normal. The CPP decreased at 24 hr (75 +/- 14 mmHg, P = 0.026) and 72 hr (73 +/- 15 mmHg, P = 0.024) from the baseline (99 +/- 17 mmHg). Conscious level improved but not significantly and CT findings did not show any exacerbation in bleeding or edema.
CONCLUSION: In patients with acute cerebral hemorrhage, nicardipine infusion to decrease blood pressure by 20 to 30% had no effect on Vmca, ICP, cerebral bleeding and edema, but decreased CPP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11132741     DOI: 10.1007/BF03019868

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  13 in total

Review 1.  Intravenous nicardipine: its use in the short-term treatment of hypertension and various other indications.

Authors:  Monique P Curran; Dean M Robinson; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Blood pressure reduction for acute intracerebral hemorrhage: how low can you go?

Authors:  Viktor Szeder; Stephan A Mayer
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

3.  Management of acute hypertensive response in patients with intracerebral hemorrhage.

Authors:  Syeda L Alqadri; Adnan I Qureshi
Journal:  Curr Atheroscler Rep       Date:  2012-08       Impact factor: 5.113

4.  Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: design, methods, and rationale.

Authors:  A I Qureshi; Y Y Palesch
Journal:  Neurocrit Care       Date:  2011-12       Impact factor: 3.210

Review 5.  Management of systemic and pulmonary hypertension.

Authors:  Jerrold H Levy
Journal:  Tex Heart Inst J       Date:  2005

6.  Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH): rationale and design.

Authors:  Adnan I Qureshi
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

7.  Antihypertensive treatment of acute cerebral hemorrhage.

Authors: 
Journal:  Crit Care Med       Date:  2010-02       Impact factor: 7.598

8.  A multicenter comparison of outcomes associated with intravenous nitroprusside and nicardipine treatment among patients with intracerebral hemorrhage.

Authors:  M Fareed K Suri; Gabriela Vazquez; Mustapha A Ezzeddine; Adnan I Qureshi
Journal:  Neurocrit Care       Date:  2009-02-18       Impact factor: 3.210

9.  Oral administration of cilnidipine to patients with hypertensive intracerebral hemorrhage in the acute stage: significance and role of an N-type calcium channel blocker.

Authors:  A Matsuno; F Ide; H Tanaka; S Asano; S Miyawaki; T Uno; J Tanaka; H Nakaguchi; M Sasaki; M Murakami; N Fuke
Journal:  Ir J Med Sci       Date:  2009-12       Impact factor: 1.568

10.  Antihypertensive treatment of acute intracerebral hemorrhage by intravenous nicardipine hydrochloride: prospective multi-center study.

Authors:  Sung-Kyun Hwang; Jong-Soo Kim; Jung Hee Kim; Chang Ki Hong; Kook Hee Yang
Journal:  J Korean Med Sci       Date:  2012-08-22       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.